-
公开(公告)号：US11059833B2
公开(公告)日：2021-07-13
申请号：US17078257
申请日：2020-10-23
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Leanne Marie Buzon , Kevin James Filipski , David Andrew Griffith , Bethany Lyn Kormos , Luis Angel Martinez-Alsina , Russell Alan Miller , Matthew Richard Reese , Rachel Jane Roth Flach , Yuan Zhang
IPC: C07D495/04 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61K45/06
Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
-
公开(公告)号：US09073871B2
公开(公告)日：2015-07-07
申请号：US14471576
申请日：2014-08-28
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: A61K31/415 , C07D231/12 , C07D207/34 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D487/04 , C07D403/12
CPC classification number: C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
公开(公告)号：US08933104B2
公开(公告)日：2015-01-13
申请号：US14334718
申请日：2014-07-18
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: C07D401/12 , A61K31/44 , C07D213/82
CPC classification number: C07D405/12 , A61K31/44 , A61K31/4427 , C07D213/74 , C07D213/81 , C07D213/82 , C07D237/08 , C07D239/42 , C07D241/28 , C07D241/34 , C07D401/12 , C07D403/12
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
公开(公告)号：US20240366598A1
公开(公告)日：2024-11-07
申请号：US18634154
申请日：2024-04-12
Applicant: Pfizer Inc.
Inventor： Kevin James Filipski , Matthew Forrest Sammons , Samuel Michael Levi , Yang Wang , Advaita Panchagnula , Yanfei Guan , Matthew Richard Reese , Luis Angel Martinez Alsina , Steven Victor O'Neil , Lei Zhang , Qifang Li , Ethan Lawrence Fisher , Danica Antonia Rankic
IPC: A61K31/506 , A61K31/403 , A61K31/4439 , A61K31/444 , A61P3/04 , C07D207/16 , C07D209/52 , C07D401/12 , C07D401/14 , C07D403/12
Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
-
公开(公告)号：US20210024536A1
公开(公告)日：2021-01-28
申请号：US16912828
申请日：2020-06-26
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Leanne Marie Buzon , Kevin James Filipski , David Andrew Griffith , Bethany Lyn Kormos , Luis Angel Martinez-Alsina , Russell Alan Miller , Matthew Richard Reese , Rachel Jane Roth Flach , Yuan Zhang
IPC: C07D495/04
Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
-
Patent Agency Ranking
公开(公告)号：US20160362392A1
公开(公告)日：2016-12-15
申请号：US15248296
申请日：2016-08-26
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: C07D401/04
CPC classification number: C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Abstract translation: 或其药学上可接受的盐，其中R1，R2，R3，A1，A2，A3，A4，L，B1，B2，B3和B4如本文所定义。 已经发现式I的化合物用作胰高血糖素拮抗剂或反向激动剂。 因此，式I化合物及其药物组合物可用于治疗由胰高血糖素介导的疾病，病症或病症。
-
公开(公告)号：US09452999B2
公开(公告)日：2016-09-27
申请号：US14730562
申请日：2015-06-04
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: A61K31/506 , C07D239/28 , C07D403/04 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D487/04 , C07D403/12
CPC classification number: C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
公开(公告)号：US20130296355A1
公开(公告)日：2013-11-07
申请号：US13934322
申请日：2013-07-03
Applicant: Pfizer Inc.
Inventor： Gary Erik Aspnes , Mary Theresa Didiuk , Kevin James Filipski , Angel Guzman-Perez , Esther Cheng Yin Lee , Jeffrey Allen Pfefferkorn , Benjamin Dawson Stevens , Meihua Mike Tu
IPC: C07D487/04 , C07D401/12 , C07D231/12 , C07D401/04 , C07D231/18 , C07D405/14 , C07D249/08 , C07D261/08 , C07D231/56 , C07D403/12 , C07D401/14 , C07D233/64 , C07D207/34
CPC classification number: C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
-
公开(公告)号：US20240336572A1
公开(公告)日：2024-10-10
申请号：US18626467
申请日：2024-04-04
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Edward Lee Conn , David Christopher Ebner , Brian Stephen Gerstenberger , Chan Woo Huh , Daniel Wei-Shung Kung , Alan Martin Mathiowetz , Jessica Gloria Katherine O'Brien , Meihua Mike Tu , Kimberly O'Keefe Cameron , Dilinie Prasadhini Fernando , Kevin James Filipski , Esther Cheng Yin Lee , Sarah Jane Mear , Aaron Christopher Smith
IPC: C07D231/56 , A61K31/416
CPC classification number: C07D231/56 , A61K31/416
Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.
-
公开(公告)号：US11542270B2
公开(公告)日：2023-01-03
申请号：US16912828
申请日：2020-06-26
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Leanne Marie Buzon , Kevin James Filipski , David Andrew Griffith , Bethany Lyn Kormos , Luis Angel Martinez-Alsina , Russell Alan Miller , Matthew Richard Reese , Rachel Jane Roth Flach , Yuan Zhang
IPC: C07D495/04 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61K45/06
Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.025 seconds)
